Blab AI
Utah Launches AI-Powered Prescription Refill Pilot, Early Results Show High Physician Agreement
In early March 2026, the state of Utah began a pilot program that lets patients renew chronic‑condition prescriptions through an artificial‑intelligence (AI) system operated by the startup Doctronic. The partnership, announced by the Utah Office of Artificial Intelligence Policy (OAIP), is the first state‑level deployment of an autonomous prescription‑refill agent.
The program permits 30‑, 60‑ or 90‑day renewals for 191 commonly prescribed drugs, including psychiatric medications and birth control. The AI recommends a renewal in 72 % of cases, and licensed physicians approve 91 % of those recommendations. When the AI denies a renewal—28 % of the time—physicians agree with the denial 69 % of the time; the remaining 31 % of denials are described by physicians as “overly cautious.” The OAIP has begun an independent review of the data.
Doctronic’s co‑founders, Matt Pavelle and Adam Oskowitz, said the pilot was designed to address medication non‑adherence, which they estimate causes 125,000 preventable deaths and costs the U.S. health system $100 billion annually. Pavelle noted that 30 % of non‑adherence stems from friction in the refill process and that the AI can eliminate one pain point.
The state’s regulatory relief program, created two years ago, allows companies to deploy AI products that lack a clear regulatory pathway under existing Utah law. Approved entities receive a temporary custom‑regulated environment for one to three years. Zach Boyd, OAIP director, said the program is intended to let the state respond “in an agile manner as AI disrupts a lot of different industries.”
Oskowitz said Utah was chosen because it hosts the most mature AI sandbox, is technology‑friendly, data‑driven, and collaborative. The OAIP’s joint working group with the Utah Medical Licensing Board was formed after the board requested the program’s suspension in April. The board’s letter noted it was unaware of the partnership until after implementation. The OAIP responded that companies must submit a detailed deployment and safety plan that is thoroughly vetted.
In the first five months of the pilot, Doctronic physicians reviewed AI interactions. When the AI requested additional information for a renewal, a second physician reviewed the case. In 97 % of those instances, either the first or second physician found the renewal appropriate based on the AI’s gathered data. The system also checks drug‑drug interactions for patients with multiple chronic conditions, a feature that has led to repeat usage “off the charts,” according to Pavelle.
The pilot’s next phases will involve sampling 10 % of cases to audit the AI’s decisions, followed by random sampling in the final phase.
Doctronic has engaged regulators in Arizona and noted that Texas and Wyoming offer similar regulatory relief programs. The U.S. Department of Health and Human Services’ Advanced Research Projects Agency for Health (ARPA‑H) launched the Advocate program to build agentic AI for cardiovascular disease management, a development that Doctronic’s leadership has cited as part of a broader governmental push to explore AI in healthcare.
The Utah pilot remains the only state‑level deployment of an autonomous prescription‑refill AI as of August 2026. The program’s outcomes will inform future regulatory frameworks, potential expansion to other states, and the broader conversation about AI’s role in routine medical care.
The program permits 30‑, 60‑ or 90‑day renewals for 191 commonly prescribed drugs, including psychiatric medications and birth control. The AI recommends a renewal in 72 % of cases, and licensed physicians approve 91 % of those recommendations. When the AI denies a renewal—28 % of the time—physicians agree with the denial 69 % of the time; the remaining 31 % of denials are described by physicians as “overly cautious.” The OAIP has begun an independent review of the data.
Doctronic’s co‑founders, Matt Pavelle and Adam Oskowitz, said the pilot was designed to address medication non‑adherence, which they estimate causes 125,000 preventable deaths and costs the U.S. health system $100 billion annually. Pavelle noted that 30 % of non‑adherence stems from friction in the refill process and that the AI can eliminate one pain point.
The state’s regulatory relief program, created two years ago, allows companies to deploy AI products that lack a clear regulatory pathway under existing Utah law. Approved entities receive a temporary custom‑regulated environment for one to three years. Zach Boyd, OAIP director, said the program is intended to let the state respond “in an agile manner as AI disrupts a lot of different industries.”
Oskowitz said Utah was chosen because it hosts the most mature AI sandbox, is technology‑friendly, data‑driven, and collaborative. The OAIP’s joint working group with the Utah Medical Licensing Board was formed after the board requested the program’s suspension in April. The board’s letter noted it was unaware of the partnership until after implementation. The OAIP responded that companies must submit a detailed deployment and safety plan that is thoroughly vetted.
In the first five months of the pilot, Doctronic physicians reviewed AI interactions. When the AI requested additional information for a renewal, a second physician reviewed the case. In 97 % of those instances, either the first or second physician found the renewal appropriate based on the AI’s gathered data. The system also checks drug‑drug interactions for patients with multiple chronic conditions, a feature that has led to repeat usage “off the charts,” according to Pavelle.
The pilot’s next phases will involve sampling 10 % of cases to audit the AI’s decisions, followed by random sampling in the final phase.
Doctronic has engaged regulators in Arizona and noted that Texas and Wyoming offer similar regulatory relief programs. The U.S. Department of Health and Human Services’ Advanced Research Projects Agency for Health (ARPA‑H) launched the Advocate program to build agentic AI for cardiovascular disease management, a development that Doctronic’s leadership has cited as part of a broader governmental push to explore AI in healthcare.
The Utah pilot remains the only state‑level deployment of an autonomous prescription‑refill AI as of August 2026. The program’s outcomes will inform future regulatory frameworks, potential expansion to other states, and the broader conversation about AI’s role in routine medical care.
